Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection - The azithromycin in coronary artery disease: Elimination of myocardial infection with Chlamydia (ACADEMIC) study

Article

关键词: C-REACTIVE PROTEIN;    HEART-DISEASE;    ATHEROSCLEROTIC PLAQUES;    CARDIOVASCULAR-DISEASE;    BLOOD MONOCYTES;    TWAR;    MACROPHAGES;    ASSOCIATION;    INFARCTION;    RUPTURE;   

DOI  :  10.1161/01.CIR.99.12.1540

来源: SCIE

【 摘 要 】

Background-Chlamydia pneumoniae commonly causes respiratory infection, is vasotropic, causes atherosclerosis in animal models, and has been found in human atheromas. Whether it plays a causal role in clinical coronary artery disease (CAD) and is amenable to antibiotic therapy is uncertain, Methods and Results-CAD patients (n=302) who had a seropositive reaction to C pneumoniae (IgG titers greater than or equal to 1:16) were randomized to receive placebo or azithromycin, 500 mg/d for 3 days, then 500 mg/wk for 3 months. Circulating markers of inflammation (C-reactive protein [CRP], interleukin [IL]-1, IL-6, and tumor necrosis factor [TNF]-alpha), C pneumoniae antibody titers, and cardiovascular events were assessed at 3 and 6 months. Treatment groups were balanced, with age averaging 64 (SD=10) years; 89% of the patients were male. Azithromycin reduced a global rank sum score of the 4 inflammatory markers at 6 (but not 3) months (P=0.011) as well as the mean global rank sum change score: 531 (SD=201) for active drugs and 587 (SD=190) for placebo (P=0.027). Specifically, change-score ranks were significantly lower for CRP (P=0.011) and IL-6 (P=0.043). Antibody titers were unchanged, and number of clinical cardiovascular events at 6 months did not differ by therapy (9 for active drug, 7 for placebo). Azithromycin decreased infections requiring antibiotics (1 versus 12 at 3 months, P=0.002) but caused more mild, primarily gastrointestinal, adverse effects (36 versus 17, P=0.003), Conclusions-In CAD patients positive for C pneumoniae antibodies, global tests of 4 markers of inflammation improved at 6 months with azithromycin. However, unlike another smaller study, no differences in antibody titers and clinical events were observed. Longer-term and larger studies of antichlamydial therapy are indicated.

【 授权许可】

Free